Tag: Treatment

  • Many children with ADHD miss a crucial step in treatment

    Many children with ADHD miss a crucial step in treatment

    When pediatricians diagnose preschoolers with attention deficit hyperactivity disorder, there are clear steps they are supposed to take.

    Families should first be referred to behavior therapy, which teaches caregivers how to better support their children and manage challenging behaviors that may be related to ADHD. If therapy isn’t making a significant difference, the American Academy of Pediatrics advises, pediatricians can then consider medication.

    Nationwide, this process — behavior therapy, then medication if needed — isn’t being followed as often as it should, according to a study recently released by Stanford Medicine and published in JAMA Network Open. Instead, more than 42 percent of 3- to 5-year-olds with ADHD were prescribed medication within a month of their diagnosis.

    Missing out on behavior therapy has worrisome implications for children and families, said Dr. Yair Bannett, assistant professor of pediatrics at Stanford Medicine and lead author of the study. Behavioral management training for parents over the course of several months has been found to reduce children’s ADHD symptoms and behavioral problems, and improve parent skills and their relationships with their children. 

    Without that support, families may be left facing additional challenges. Behavioral training “reduces the chaos in the house and can improve the quality of life for the parents and the child,” Bannett said. 

    There are several reasons families may be missing this intervention. Some pediatricians aren’t familiar with the purpose of behavior therapy, Bannett added, which is specifically aimed at the adults who support children with ADHD, not the children. “It’s really more of an advanced type of parenting course,” he said. Families also may have trouble finding affordable local therapists.

    Bannett said parents should use three key practices to support young children with ADHD. (These strategies also work well for teachers, he added.)

    Focus on building a strong, positive relationship: Having a strong attachment between the child and parent or teacher is an important first step to managing behavior, Bannett said. That means spending quality one-on-one time with the child. “That’s the child’s motivation, they want to please you,” he added. “Without that first piece, none of this will work.”

    Use positive reinforcement: Rather than punishing a child’s negative behavior, Bannett said, parents and teachers will see more success if they praise good behaviors and develop reward systems to encourage them.  

    Adjust the child’s environment: Children with ADHD may thrive with simple environmental changes, such as “visual schedules” — charts that use pictures to show a child daily activities or tasks — and a consistent, structured routine.

    Parents who can’t find in-person therapists can substitute online therapy, Bannett said. The training is also useful for families even after their children are prescribed medication. 

    To make sure more families have access to helpful strategies, Bannett would like to see more education for doctors and clinicians on these best practices. 

    “The pediatricians could also counsel families in the office about these techniques,” Bannett said. “Some written materials and resources could be enough” to at least introduce these practices, he added. “That’s what I’m hoping could make a change.”

    Reading list

    This story about children with ADHD was produced by The Hechinger Report, a nonprofit, independent news organization focused on inequality and innovation in education. Sign up for the Hechinger newsletter.

    The Hechinger Report provides in-depth, fact-based, unbiased reporting on education that is free to all readers. But that doesn’t mean it’s free to produce. Our work keeps educators and the public informed about pressing issues at schools and on campuses throughout the country. We tell the whole story, even when the details are inconvenient. Help us keep doing that.

    Join us today.

    Source link

  • White House Floats Compact for Preferential Treatment

    White House Floats Compact for Preferential Treatment

    The Trump administration has asked nine universities to sign on to a proposed compact, mandating certain changes in exchange for preferential treatment on federal funding.

    First reported by The Washington Post and confirmed, with additional details, by The Wall Street Journal, the proposal seeks an agreement with nine institutions that are being asked to commit to a 10-point memo referred to as the “Compact for Academic Excellence in Higher Education.”

    Among the various conditions, institutions are reportedly being asked to:

    • Ban consideration of race or sex in hiring and admissions processes
    • Freeze tuition for a five-year period
    • Limit international undergraduate enrollment to 15 percent of the student body
    • Commit to institutional neutrality
    • Require applicants to take standardized tests, such as the SAT or ACT
    • Clamp down on grade inflation
    • Ensure a “vibrant marketplace of ideas on campus” 
    • Restrict employees from expressing political views on behalf of the institution
    • Shut down departments that “punish, belittle” or “spark violence against conservative ideas”
    • Anonymously poll students and employees on compact compliance and publish the results

    Another requirement mandates that signatories “deploy their endowments to the public good,” such as by not charging tuition to students “pursuing hard science programs (with exceptions, as desired, for families of substantial means)” for universities with more than $2 million per undergraduate student in endowment assets. Universities would also be required to post more details about graduates’ earnings and refund tuition to those who drop out in their first semester.

    After leveraging funding freezes and other tactics to pressure colleges to make changes, the compact reflects a different approach from the administration while still geared toward the same goal—remaking higher education in Trump’s image. May Mailman, a Trump adviser, hinted at the plan in a New York Times interview a week before the proposal emerged, saying it could be a way for universities to affirm they are “doing the right things.”

    “The Trump administration does not want to be all Whac-a-Mole or all negative, but these are the principles that universities and the Trump administration and, frankly, private donors can ascribe to to say, ‘This makes a great university,’” she told the Times.

    Institutions reportedly invited to join are: Brown University, Dartmouth College, the Massachusetts Institute of Technology, the University of Arizona, the University of Pennsylvania, the University of Southern California, University of Texas at Austin, the University of Virginia and Vanderbilt University.

    Those that agree will receive “multiple positive benefits,” including “substantial and meaningful federal grants,” according to a copy of the memo published by The Washington Examiner.

    But failure to comply with the agreement would come with steep consequences. Noncompliant universities would “lose access to the benefits of this agreement” for a year. Subsequent violations would lead to a two-year punishment. And the federal government could claw back “all monies advanced by the U.S. government during the year of any violation.” Private donations would also be required to be returned, upon request.

    The Department of Justice would be tasked to enforce the agreements.

    Institutional Responses

    Most universities did not respond to requests for comment from Inside Higher Ed. But Texas officials seem eager to sign on, sharing a statement indicating their enthusiasm for the compact.

    University of Texas system Board of Regents chairman Kevin P. Eltife wrote in the statement that the flagship was “honored” to be among the institutions “selected by the Trump Administration for potential funding advantages” under the proposed compact, which it is currently reviewing.

    “Higher education has been at a crossroads in recent years, and we have worked very closely with Governor [Greg] Abbott, Lt. Gov. [Dan] Patrick and Speaker [Dustin] Burrows to implement sweeping changes for the benefit of our students and to strengthen our our [sic] institutions to best serve the people of Texas,” Eltife wrote. “Today we welcome the new opportunity presented to us and we look forward to working with the Trump Administration on it.”

    University of Virginia spokesperson Brian Coy told Inside Higher Ed by email that interim president Paul Mahoney “created a working group under the leadership of Executive Vice President and Provost Brie Gertler and Executive Vice President and Chief Operating Officer J.J. Davis to advise him” on UVA’s response to the letter but has not yet made a decision to sign or not.

    USC simply said in a statement, “We are reviewing the Administration’s letter.”

    Both the White House and the Department of Education initially responded to requests for comment with automatic replies because of the federal government shutdown, which began Wednesday. A press office official later responded only to confirm The Wall Street Journal’s reporting.

    Outside Perspectives

    News of the proposal prompted a flurry of criticism within academic circles.

    American Association of University Professors president Todd Wolfson blasted the idea in a Thursday statement and called on governing boards to reject it.

    “The Trump administration’s offer to give preferential treatment to colleges and universities that court government favor stinks of favoritism, patronage, and bribery in exchange for allegiance to a partisan ideological agenda. This compact is akin to a loyalty oath. Adherence by university administrations would usher in a new era of thought policing in American higher education,” Wolfson wrote.

    The executive committee of Penn’s AAUP chapter also opposed the proposal.

    The Foundation for Individual Rights and Expression also criticized it in a post on X, writing that “the compact includes troubling language” specifically pointing to the call to eliminate academic departments critical of conservative ideas, which it cast as undermining free speech.

    “A government that can reward colleges and universities for speech it favors today can punish them for speech it dislikes tomorrow. That’s not reform. That’s government-funded orthodoxy,” FIRE officials wrote.

    Trinity Washington University president Pat McGuire called the proposal “political extortion.”

    Brendan Cantwell, a higher education professor at Michigan State University, told Inside Higher Ed there are multiple issues with the proposal, including vague language about political speech that could allow universities or the federal government to single out faculty members for publicly discussing topics within their expertise. He added that “enforcement is so vague” that it would be easy for the federal government to declare universities out of compliance with the agreement.

    Cantwell suggested, “This is probably a bigger deal than the Columbia [settlement] because it’s creating an incentive structure” that spurs universities to go along or opens them up to retaliation from the federal government, making it risky whether a university signs on or not.

    (Columbia agreed to far-reaching changes to admissions, hiring, disciplinary processes and more in July, including a $221 million fine, when it reached a deal with the federal government to settle over findings that it failed to properly police antisemitism on campus. Columbia did not admit to wrongdoing, but administrators have acknowledged the need for reforms.)

    Brian L. Heuser, a Vanderbilt professor and long-standing member of the university’s Faculty Senate, urged fellow senators and other faculty colleagues to organize against the idea in an email shared with Inside Higher Ed. Heuser called the compact “a dangerous departure from the core values that should underpin our institutions—namely, free inquiry, open debate, and institutional autonomy” and argued that it endangers academic freedom, among other concerns.

    But some conservatives have lauded the idea and want ED to push harder.

    “Secretary [Linda] McMahon deserves credit for working to disincentivize the use of race or sex in college admissions,” U.S. Sen. Todd Young, an Indiana Republican, wrote in a social media post. “We must go further—federally accredited institutions should eliminate ALL preferences grounded in ancestry, such as legacy status, or other factors unrelated to merit.”

    Why These 9?

    While it is unclear how the federal government landed on the nine schools as candidates for the proposal, one official told The Wall Street Journal the Trump administration believed they would be “good actors.” But contextual clues offer insights into why some may have been picked.

    Of the nine, only five presidents signed on to a letter published earlier this year by higher education organizations pushing back on government overreach and political interference, which ultimately gathered 662 signatures. Of those five presidents, one has since resigned: Jim Ryan at UVA, who faced pressure from the Trump administration after it claimed the university failed to fully dismantle diversity, equity and inclusion programs.

    Two institutions—Brown and Penn—previously struck deals with the federal government.

    Others have drawn attention for political reasons. At Vanderbilt, Chancellor Daniel Diermeier has emerged as a leading voice advocating for institutional neutrality and has clashed with other campus leaders, arguing that higher education is in desperate need of reform, agreeing with frequent conservative criticisms of the sector. And Texas—one of three public institutions on the list—has an overwhelmingly conservative board, and both the system and flagship are led by former Republican elected officials.

    Source link

  • Shaping the Future of Cancer Treatment and Advocating for Women in STEM

    Shaping the Future of Cancer Treatment and Advocating for Women in STEM

    Megan O’Meara, M.D., head of early-stage development at Pfizer Oncology, is deeply committed to scientific innovation, mentorship, and breaking barriers for the next generation of women in science, technology, engineering, and mathematics (STEM) industries. In this conversation, Megan shares her journey in oncology, leadership philosophy, and vision of a world where people with cancer live better and longer lives.

    Megan O’Meara, M.D.

    Head of Early-Stage Development, Pfizer Oncology

    What drew you to pursue a career in oncology and what is it that inspires you most about working in this field?

    I’ve always been curious about science. My grandfather was a pediatrician, and as a child he read books to me about the history of medicine. In high school, I worked in cancer research labs, and that gave me exposure to the field from an early age. By the time I was in college, there were exciting advancements happening, including broader use of tumor profiling and targeted therapies. I felt there was a huge opportunity to transform cancer treatment, and I knew I wanted to be part of it. I pursued my medical degree and later went into academic research before transitioning to industry, where I felt I might have the broadest impact on the greatest number of people.

    Women make up less than 30% of the global STEM workforce. What has your experience been as a woman in research?

    Being a woman in a historically male-dominated field can come with unique challenges and opportunities. There were times when I was the only woman in the room. On occasion, I felt like the only one leaving the office on time to make dinner for my family and worried about missing opportunities or important conversations that were happening when I wasn’t there.

    Over time, I learned to accept the situation and be confident in setting personal boundaries. I inserted myself in different ways and advanced my career without losing who I am. I developed the confidence to be me — bringing my most authentic and whole self to work. Now, I encourage and empower other women to do the same.

    As an industry, there’s still a long way to go. At a recent oncology conference, research showed that men presenting were introduced as “Dr.” while women were introduced by their first names. It seems nuanced, but it reflects a larger issue. Even in a field like oncology, where we pride ourselves on progress, bias still exists in subtle but pervasive ways. Things are improving, but they’re not where they should be yet. That’s why I feel so strongly about uplifting other women and creating opportunities for women in science.


    Learn more about Pfizer Oncology at Let’s Outdo Cancer.


    How are you working to change the research field to be more inclusive and supportive of women?

    There were many people, particularly female leaders, throughout my career who saw my potential and championed my advancement. I try to do the same for all my team at Pfizer, including the talented women that work with me. I mention their names when I’m in a room with other leaders; I look for opportunities that will showcase their potential.

    Outside of work, I volunteer at my daughter’s elementary school to organize events that engage students with science, such as bringing in Pfizer scientists to demonstrate lab techniques like DNA isolation and talk about how science can be applied to areas they are interested in. Studies show that girls start losing interest in science around age 12, so, if we can work to address that early, it can make a difference in improving female representation in STEM fields.

    I’m also active in the Society for Immunotherapy in Cancer (SITC) Women in Cancer Immunotherapy Network. I’ve spoken about my journey in research at their events, which are often attended by many women in both academia and industry who are at a crossroads in their career. They’re wondering, “Can I do this?” Hearing people’s stories about how they made it work can be incredibly inspiring.

    As head of the division at Pfizer Oncology responsible for developing innovative cancer treatments, what excites you most about the work your team is currently doing?

    Right now, I’m particularly excited about our work in antibody-drug conjugates (ADCs). ADCs are innovative cancer medicines that specifically target cancer cells and deliver cancer-killing drugs ​directly to tumors, while sparing more of the healthy cells in the body. ​

    ADCs have been the foundation of my career, having worked in the space for almost 15 years. This depth of experience, knowledge, and history is being applied now to what we’re doing at Pfizer to advance the field. And we’ve had a huge impact already — bringing treatments to people with blood cancer for the first time in decades and significantly changing the standard of care across tumor types.

    Now, as a company, we’re asking, “How do we make ADCs even safer and more effective?” We’re exploring new drug linkers, different payloads, and novel combinations, all with the goal of giving patients better options. This kind of innovation is why I pursued a career in STEM — it’s tremendously fulfilling to be bringing us closer to a world where people with cancer live better and longer lives.

    How is Pfizer uniquely positioned to make progress in cancer treatment?

    I like to say Pfizer embodies a spirit of innovation and we have some of the most brilliant and dedicated scientists I’ve ever worked with. It’s rare to work at a company, even in big pharma, that has demonstrated leadership across multiple modalities of science the way Pfizer has. We’re constantly learning, adapting, and investing in what’s next across a wide pipeline of products. It’s an amazing powerhouse to be a part of.

    For me, our success is also due to a culture — set by our executives — where each person has the opportunity to thrive. Chris Boshoff, chief scientific officer and president, R&D, is passionate about showcasing the team and giving people opportunities. I’ve experienced the same from other leaders. When I first joined Pfizer, Sally Susman, executive vice president and chief corporate affairs officer, introduced herself and said, “Next time you’re in New York, come meet my team.” She brought me into her leadership meeting and helped me build connections. These are just two of many people that have gone out of their way to create an environment where I am able to bring my best self to work, and I am doing the same to ensure my team of scientists has everything they need to succeed.

    What do you hope for the future of women in STEM?

    I hope that in 20 years, women don’t have to navigate as many barriers. I hope everyone can bring their whole self to the table without feeling like they need to sacrifice a piece of their personal life to succeed. Instead of feeling impostor syndrome around big opportunities, I hope women ask themselves, “Why not me?”

    We still have work to do, but I truly believe we’re making progress. By supporting women, we’re supporting a better industry and better science.


    Learn more about Pfizer Oncology at Let’s Outdo Cancer.


    Source link